WuXi PharmaTech and PRA have signed a joint venture agreement to offer Phase I-IV clinical trial services in China, Hong Kong and Macau. The JV will provide clinical trial monitoring, project management, regulatory strategy and submissions, data management, biostatistics, drug safety reporting, and medical monitoring. WuXi and PRA will combine their clinical operations in China to operate as an independent CRO and will be jointly owned by their respective parent companies.    WuXi will contribut...